Osteosarcoma (OS) is the most common primary malignant bone tumor, which usually occurs in children and adolescents. It is generally a high-grade malignancy presenting with extreme metastases to the lungs or other bones. The etiology of the disease is multifaceted and still remains obscure. A combination of surgery and chemotherapy has played a major role in the treatment of OS over the past three decades, and consequently, the overall survival rates for the disease have remained unchanged. Therefore, there is an urgent need to employ new comprehensive analyses and technologies to develop significantly more informative classification systems, with the aim of developing more effective and less toxic therapies for OS patients. This review discusses the existing knowledge of OS therapy and potential methods to develop novel therapeutic agents for the disease.
LeeDYStaddonAPShabasonJESebroR. Phase I and phase II clinical trials in sarcoma: implications for drug discovery and development.Cancer Med2019;8:585–92
2.
ConstantinidouAPollackSLoggersERodlerEJonesRL. The evolution of systemic therapy in sarcoma.Expert Rev Anticancer Ther2013;13:211–23
3.
HelmanLJMeltzerP. Mechanisms of sarcoma development.Nat Rev Cancer2003;3:685–94
4.
RothzergEHoXDXuJWoodDMartsonAMaasaluKKoksS. Alternative splicing of leptin receptor overlapping transcript in osteosarcoma.Exp Biol Med2020;245:1437–43
5.
LuetkeAMeyersPALewisIJuergensH. Osteosarcoma treatment – where do we stand? A state of the art review.Cancer Treat Rev2014;40:523–32
6.
ZhangPLiJ. Down-regulation of circular RNA hsa_circ_0007534 suppresses cell growth by regulating miR-219a-5p/SOX5 axis in osteosarcoma.J Bone Oncol2021;27:100349
7.
YarmishGKleinMJLandaJLefkowitzRAHwangS. Imaging characteristics of primary osteosarcoma: nonconventional subtypes.Radiographics2010;30:1653–72
DurfeeRAMohammedMLuuHH. Review of osteosarcoma and current management.Rheumatol Ther2016;3:221–43
10.
AndoKHeymannMFStresingVMoriKRediniFHeymannD. Current therapeutic strategies and novel approaches in osteosarcoma.Cancers2013;5:591–616
11.
ChenZZhangPXuYYanJLiuZLauWBLauBLiYZhaoXWeiYZhouS. Surgical stress and cancer progression: the twisted tango.Mol Cancer2019;18:132
12.
GottschalkASharmaSFordJDurieuxMETiouririneM. Review article: the role of the perioperative period in recurrence after cancer surgery.Anesth Analg2010;110:1636–43
13.
CarrleDBielackSS. Current strategies of chemotherapy in osteosarcoma.Int Orthop2006;30:445–51
14.
HarrisonDJGellerDSGillJDLewisVOGorlickR. Current and future therapeutic approaches for osteosarcoma.Expert Rev Anticancer Ther2018;18:39–50
15.
PadmanabhanSTripathiDNVikramARamaraoPJenaGB. Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: intervention of folic and folinic acid.Mutat Res2009;673:43–52
16.
WittigJCBickelsJPriebatDJelinekJKellar-GraneyKShmooklerBMalawerMM. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment.Am Fam Physician2002;65:1123–32
17.
JanewayKAGrierHE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.Lancet Oncol2010;11:670–8
18.
CrewsKRLiuTRodriguez-GalindoCTanMMeyerWHPanettaJCLinkMPDawNC. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.Cancer2004;100:1724–33
19.
XuMXuSFYuXC. Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy.Curr Oncol2014;21:e678–84
20.
GrafNWinklerKBetlemovicMFuchsNBodeU. Methotrexate pharmacokinetics and prognosis in osteosarcoma.J Clin Oncol1994;12:1443–51
21.
JaffeNGorlickR. High-dose methotrexate in osteosarcoma: let the questions surcease – time for final acceptance.J Clin Oncol2008;26:4365–6
22.
ArcamoneFCassinelliGFantiniGGreinAOrezziPPolCSpallaC. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Reprinted from Biotechnology and Bioengineering, Vol. XI, Issue 6, Pages 1101–1110 (1969).Biotechnol Bioeng2000;67:704–13
23.
Cortes-FunesHCoronadoC. Role of anthracyclines in the era of targeted therapy.Cardiovasc Toxicol2007;7:56–60
24.
ThornCFOshiroCMarshSHernandez-BoussardTMcLeodHKleinTEAltmanRB. Doxorubicin pathways: pharmacodynamics and adverse effects.Pharmacogenet Genomics2011;21:440–6
25.
LonghiAFerrariSBacciGSpecchiaS. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma.Anticancer Drugs2007;18:737–44
26.
TchounwouPBDasariSNoubissiFKRayPKumarS. Advances in our understanding of the molecular mechanisms of action of cisplatin in CANCER THERAPY.J Exp Pharmacol2021;13:303–28
27.
DasariSTchounwouPB. Cisplatin in cancer therapy: molecular mechanisms of action.Eur J Pharmacol2014;740:364–78
28.
SzentmihalyiKBlazovicsAMayZMohaiMJrSuleKAlbertMSzenasiGSebestenyAMatheC. Metal element alteration in the lung by cisplatin and CV247 administration.Biomed Pharmacother2020;128:110307
29.
SprangersBLapmanS. The growing pains of ifosfamide.Clin Kidney J2020;13:500–3
30.
SarbayHDemirUFYilmazGAtayAAMalboraB. Ifosfamide induced encephalopathy in a child with osteosarcoma.J Oncol Pharm Pract2021;27:1302–6
31.
RothzergEIngleyEMullinBXueWWoodDXuJ. The hippo in the room: targeting the hippo signalling pathway for osteosarcoma therapies.J Cell Physiol2021;236:1606–15
32.
StephensonMLZamecnikPC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.Proc Natl Acad Sci USA1978;75:285–8
33.
SteinCACastanottoD. FDA-approved oligonucleotide therapies in 2017.Mol Ther2017;25:1069–75
34.
RinaldiCWoodMJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders.Nat Rev Neurol2018;14:9–21
35.
OpalinskaJBGewirtzAM. Nucleic-acid therapeutics: basic principles and recent applications.Nat Rev Drug Discov2002;1:503–14
36.
MuntoniFWoodMJ. Targeting RNA to treat neuromuscular disease.Nat Rev Drug Discov2011;10:621–37
37.
EversMMToonenLJvan Roon-MomWM. Antisense oligonucleotides in therapy for neurodegenerative disorders.Adv Drug Deliv Rev2015;87:90–103
38.
PotaczekDPGarnHUngerSDRenzH. Antisense molecules: a new class of drugs.J Allergy Clin Immunol2016;137:1334–46
39.
RobertsTCLangerRWoodMJA. Advances in oligonucleotide drug delivery.Nat Rev Drug Discov2020;19:673–94
40.
WanJBaumanJAGraziewiczMASazaniPKoleR. Oligonucleotide therapeutics in cancer.Cancer Treat Res2013;158:213–33
41.
CrookeSTBakerBFCrookeRMLiangXH. Antisense technology: an overview and prospectus.Nat Rev Drug Discov2021;20:427–53
42.
SinghATrivediPJainNK. Advances in siRNA delivery in cancer therapy.Artif Cells Nanomed Biotechnol2018;46:274–83
43.
OhYKParkTG. siRNA delivery systems for cancer treatment.Adv Drug Deliv Rev2009;61:850–62
44.
KanastyRDorkinJRVegasAAndersonD. Delivery materials for siRNA therapeutics.Nat Mater2013;12:967–77
45.
AhmadzadaTReidGMcKenzieDR. Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer.Biophys Rev2018;10:69–86
46.
SchermanDRousseauABigeyPEscriouV. Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.Gene Ther2017;24:151–6
47.
SajidMIMoazzamMKatoSYeseom ChoKTiwariRK. Overcoming barriers for siRNA therapeutics: from bench to bedside.Pharmaceuticals2020;13:294
48.
HoySM. Patisiran: first global approval.Drugs2018;78:1625–31
49.
ScottLJ. Givosiran: first approval.Drugs2020;80:335–9
50.
ScottLJKeamSJ. Lumasiran: first approval.Drugs2021;81:277–82
51.
DamaseTRSukhovershinRBoadaCTaraballiFPettigrewRICookeJP. The limitless future of RNA therapeutics.Front Bioeng Biotechnol2021;9:628137
52.
WolffJAMaloneRWWilliamsPChongWAcsadiGJaniAFelgnerPL. Direct gene transfer into mouse muscle in vivo.Science1990;247:1465–8
53.
PardiNHoganMJPorterFWWeissmanD. mRNA vaccines – a new era in vaccinology.Nat Rev Drug Discov2018;17:261–79
54.
SahinUKarikoKTureciO. mRNA-based therapeutics – developing a new class of drugs.Nat Rev Drug Discov2014;13:759–80
55.
BrunoBJMillerGDLimCS. Basics and recent advances in peptide and protein drug delivery.Ther Deliv2013;4:1443–67
56.
D’HondtMBrackeNTaevernierLGevaertBVerbekeFWynendaeleEDe SpiegeleerB. Related impurities in peptide medicines.J Pharm Biomed Anal2014;101:2–30
57.
CraikDJFairlieDPLirasSPriceD. The future of peptide-based drugs.Chem Biol Drug Des2013;81:136–47
58.
KagerLPotschgerUBielackS. Review of mifamurtide in the treatment of patients with osteosarcoma.Ther Clin Risk Manag2010;6:279–86
59.
PunzoFBelliniGTortoraCPintoDDArgenzianoMPotaEPaolaADMartinoMDRossiF. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells.Oncotarget2020;11:687–98
60.
ZouYMaDWangY. The PROTAC technology in drug development.Cell Biochem Funct2019;37:21–30
61.
BenantiJA. Coordination of cell growth and division by the ubiquitin-proteasome system.Semin Cell Dev Biol2012;23:492–8
62.
TanakaK. The proteasome: overview of structure and functions.Proc Jpn Acad Ser B Phys Biol Sci2009;85:12–36
63.
PaivaSLCrewsCM. Targeted protein degradation: elements of PROTAC design.Curr Opin Chem Biol2019;50:111–9
64.
SunXGaoHYangYHeMWuYSongYTongYRaoY. PROTACs: great opportunities for academia and industry.Signal Transduct Target Ther2019;4:64
65.
QiSMDongJXuZYChengXDZhangWDQinJJ. PROTAC: an effective targeted protein degradation strategy for cancer therapy.Front Pharmacol2021;12:692574
66.
HopkinsALGroomCR. The druggable genome.Nat Rev Drug Discov2002;1:727–30
67.
GurevichEVGurevichVV. Therapeutic potential of small molecules and engineered proteins.Handb Exp Pharmacol2014;219:1–12
68.
RaoMSGuptaRLiguoriMJHuMHuangXMantenaSRMittelstadtSWBlommeEAGVan VleetTR. Novel computational approach to predict off-target interactions for small molecules.Front Big Data2019;2:25
69.
SuraweeraAO’ByrneKJRichardDJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi.Front Oncol2018;8:92
70.
WirriesAJabariSJansenEPRothSFigueroa-JuarezEWissniowskiTTNeureiterDKlieserELechlerPRuchholtzSBartschDKBoeseCKDi FazioP. Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma.Oncotarget2018;9:32997–3010
71.
ChaiyawatPPruksakornDPhanphaisarnATeeyakasemPKlangjorhorJSettakornJ. Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.Mod Pathol2018;31:264–74
72.
HoySM. Tazemetostat: first approval.Drugs2020;80:513–21
73.
NogueiraTSouzaM. New FDA oncology small molecule drugs approvals in 2020: mechanism of action and clinical applications.Bioorg Med Chem2021;46:116340
